Anaesthetic management of patients with sleep apnoea syndrome.
OBJECTIVE
Sleep apnoea syndrome (SAS) is a relatively common, potentially fatal, disorder. Patients with SAS exhibit repetitive, often prolonged episodes of apnoea during sleep, with serious nocturnal and diurnal physiologic derangements. Several anecdotal reports and clinical studies have documented anaesthetic-related occurrence of fatal and near-fatal respiratory complications in these patients. The purpose of this article is to outline the potential problems encountered in anaesthetic management of adult SAS patients, and to suggest a practical approach for anaesthesia both for incidental and specific procedures.


RESULTS
SASs have many implications for the anaesthetist. First, SAS patients are exquisitely sensitive to all central depressant drugs, with upper airway obstruction or respiratory arrest occurring even with minimal doses. Thus sedative and opioid premedication should be omitted as should the intra and postoperative use of opioids be limited or avoided. All anaesthetic drugs should be administered by titration to desired effect, preferably using short-acting drugs. When feasible, continuous regional anaesthesia using a catheter is the technique of choice. Where possible nonopioid analgesics or local anaesthetics should be used for postoperative analgesia. Perioperative monitoring for apnoea, desaturation, and dysrhythmias is essential. Secondly, SAS patients have a potentially difficult airway. Awake intubation is the safest approach to airway control. Extubation should only be tried in the fully conscious patient with intact upper airway function and under controlled situations. Thirdly, the cardiorespiratory complication of SAS and the presence of associated diseases can adversely influence anaesthetic management.


CONCLUSIONS
Perioperative risks attending SAS patients emphasize the importance of their detection, perioperative evaluation and planning.
Boushra
N N
NN
Department of Anaesthesia, Al-Salam Teaching Hospital, Cairo, Egypt.
D000328:Adult; D000402:Airway Obstruction / Q000139:chemically induced; D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage; D000765:Anesthesia, Conduction; D000768:Anesthesia, General; D018681:Anesthetics, General / Q000008:administration & dosage; D000779:Anesthetics, Local / Q000008:administration & dosage; D001049:Apnea / Q000139:chemically induced; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000009:adverse effects; D007442:Intubation, Intratracheal; D016343:Monitoring, Intraoperative; D009294:Narcotics / Q000008:administration & dosage / Q000009:adverse effects; D009466:Neuromuscular Blocking Agents / Q000008:administration & dosage / Q000009:adverse effects; D011229:Preanesthetic Medication / Q000009:adverse effects; D012119:Respiration; D012891:Sleep Apnea Syndromes / Q000150:complications* / Q000503:physiopathology
D018712:Analgesics, Non-Narcotic; D018681:Anesthetics, General; D000779:Anesthetics, Local; D006993:Hypnotics and Sedatives; D009294:Narcotics; D009466:Neuromuscular Blocking Agents